Rónán Mullen (Independent) | Oireachtas source

I did ask the question very specifically. A lot of other extraneous issues have been brought up here. I am dealing with the issue of orphan medicinal products. I asked the witnesses if there is undone work in terms of the 2014 national rare disease plan and if this is the case, why? I also want to know if Ireland were to provide the drugs on the same basis as is done in Germany, so that the same number of drugs of the orphan medicine would be available, what would be the extra costs? I imagine it is some percentage of €1 billion, but would the witnesses know what the figure is?